Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4017 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1) AZD4017 | EXPERIMENTAL | Europe: 200 mg AZD4017 |
| 2) Placebo | PLACEBO_COMPARATOR | Europe: placebo |
| 3) AZD4017 | EXPERIMENTAL | USA: 800 mg AZD4017 |
| 4) Placebo | PLACEBO_COMPARATOR | USA: placebo |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD4017 | DRUG | tablet, oral, one tablet once daily, 28 days |
| Placebo | DRUG | matching placebo tablet, oral, one tablet once daily, 28 days |
Inclusion Criteria: * Must have a diagnosis of intra-ocular hypertension (raised IOP), or primary open-angle glaucoma (POAG), with IOP \>20 mmHg and ≤36 mmHg in the study eye, and is currently prescribed a stable dose of a single anti-glaucoma medication that began at least 30 days prior to the scr...
AZD4017 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN). It has been studied in clinical trials for type 2 diabetes mellitus, obesity, and raised intraocular pressure. It is not yet approved and remains in clinical development.
AZD4017 has been evaluated in clinical trials for type 2 diabetes mellitus, obesity, and raised intraocular pressure. These studies were conducted in the United States, Sweden, and the United Kingdom. It is an investigational agent and is not approved for any indication.
AZD4017 targets HSD11B1 (11 beta hydroxysteroid dehydrogenase type 1). It acts as an inhibitor of this enzyme. This target is relevant to metabolic conditions such as type 2 diabetes and obesity, as well as raised intraocular pressure.
AZD4017 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical trials evaluating AZD4017 in metabolic and ocular conditions.
AZD4017 has completed Phase 1 and Phase 2a clinical trials. The Phase 1 studies enrolled healthy volunteers, while the Phase 2a study evaluated the drug in patients with raised intraocular pressure. It is not approved and remains investigational.
AZD4017 has been studied in three completed trials: NCT01173471, a Phase 2a study in raised intraocular pressure; NCT01096004, a Phase 1 study in obesity; and NCT00841048, a Phase 1 study in type 2 diabetes. All trials are completed.